Efficacy and Safety of Posiphen and its Precursor Phenserine in Alzheimer’sDisease: a Systematic Review
The reviewed studies suggest that Phenserine and Posiphen may improve cognitive function and reduce Alzheimer's disease biomarkers and markers of neuroinflammation present in cerebrospinal fluid. However, small sample sizes and variability in dosages limit the generalizability of these findings. Future trials with larger cohorts and standardized protocols are needed to validate these results.
Authors
- Kevin Gustavo dos Santos Silva (ORCID: https://orcid.org/0000-0001-9286-5244)
- Carlos Rocha Oliveira (ORCID: https://orcid.org/0000-0002-2662-8379)
- Gabriela Oliveira do Nascimento
- Pedro Augusto Rodrigues Vinhas
Institutions
- Anhembi Morumbi University (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103854
- Primary Topic
- Cholinesterase and Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00